Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017606477> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2017606477 endingPage "A661" @default.
- W2017606477 startingPage "A661" @default.
- W2017606477 abstract "The FDA warned on June 15, 2011 of the bladder cancer risk associated with pioglitazone use. Therefore, we conducted a retrospective review of pioglitazone use in our hospital, to find out high risk patient, provide FDA safety advice by using electronic message in computerized physician order entry system (CPOE), aim to ensure physician aware of the risk at the moment of patient clinic visit. We included outpatients with pioglitazone use from January 1, 2006 through July 31, 2011. For high risk patients, who are male, prescribed pioglitazone more than 1 year and cumulative dose reached 28000mg, clinical pharmacists will established warning message in CPOE. The message was to inform physician the patient was at high risk for bladder cancer, and should care about the symptoms of bladder cancer, such as hematuria; urgent need to urinate or pain while urinating; pain in back or lower abdomen. Overall 3196 patients had ever prescribed pioglitazone. The mean age was 63.2 ± 11.9 years, and 1519 (49%) of the patients were male. Five (0.16%) patients with the diagnosis of bladder cancer. There were 1874 patients with currently pioglitazone use, 629 (33.5%) patients prescribed pioglitazone more than 1 year, 160 (8.5%) patients cumulative dose reached 28000mg, and 75 (4%) of our patients were at high risk for bladder cancer. Eighteen (24%) high risk patients were discontinued pioglitazone after FDA announcement, another 18 (24%) patients because of warning message established by clinical pharmacists. Twenty six (66.7%) patients have urine test, 5 (12.8%) with positive occult blood. From the retrospective results, there was no association between pioglitazone use and bladder cancer in our hospital. The communication by using electronic message in CPOE enhanced the awareness of physician. Clinical pharmacists will prospectively establish the warning message for patient with high risk." @default.
- W2017606477 created "2016-06-24" @default.
- W2017606477 creator A5015402579 @default.
- W2017606477 creator A5028097078 @default.
- W2017606477 creator A5078240628 @default.
- W2017606477 date "2012-11-01" @default.
- W2017606477 modified "2023-09-26" @default.
- W2017606477 title "PDB16 Prospective and Retrospective Safety Review of Pioglitazone in a Medical Center" @default.
- W2017606477 doi "https://doi.org/10.1016/j.jval.2012.08.347" @default.
- W2017606477 hasPublicationYear "2012" @default.
- W2017606477 type Work @default.
- W2017606477 sameAs 2017606477 @default.
- W2017606477 citedByCount "0" @default.
- W2017606477 crossrefType "journal-article" @default.
- W2017606477 hasAuthorship W2017606477A5015402579 @default.
- W2017606477 hasAuthorship W2017606477A5028097078 @default.
- W2017606477 hasAuthorship W2017606477A5078240628 @default.
- W2017606477 hasBestOaLocation W20176064771 @default.
- W2017606477 hasConcept C121608353 @default.
- W2017606477 hasConcept C126322002 @default.
- W2017606477 hasConcept C134018914 @default.
- W2017606477 hasConcept C167135981 @default.
- W2017606477 hasConcept C194828623 @default.
- W2017606477 hasConcept C2777180221 @default.
- W2017606477 hasConcept C2778384471 @default.
- W2017606477 hasConcept C2780352672 @default.
- W2017606477 hasConcept C555293320 @default.
- W2017606477 hasConcept C71924100 @default.
- W2017606477 hasConceptScore W2017606477C121608353 @default.
- W2017606477 hasConceptScore W2017606477C126322002 @default.
- W2017606477 hasConceptScore W2017606477C134018914 @default.
- W2017606477 hasConceptScore W2017606477C167135981 @default.
- W2017606477 hasConceptScore W2017606477C194828623 @default.
- W2017606477 hasConceptScore W2017606477C2777180221 @default.
- W2017606477 hasConceptScore W2017606477C2778384471 @default.
- W2017606477 hasConceptScore W2017606477C2780352672 @default.
- W2017606477 hasConceptScore W2017606477C555293320 @default.
- W2017606477 hasConceptScore W2017606477C71924100 @default.
- W2017606477 hasIssue "7" @default.
- W2017606477 hasLocation W20176064771 @default.
- W2017606477 hasOpenAccess W2017606477 @default.
- W2017606477 hasPrimaryLocation W20176064771 @default.
- W2017606477 hasRelatedWork W1986410768 @default.
- W2017606477 hasRelatedWork W2033522292 @default.
- W2017606477 hasRelatedWork W2042938358 @default.
- W2017606477 hasRelatedWork W2044774310 @default.
- W2017606477 hasRelatedWork W2115946307 @default.
- W2017606477 hasRelatedWork W2121496639 @default.
- W2017606477 hasRelatedWork W2163547766 @default.
- W2017606477 hasRelatedWork W2369716685 @default.
- W2017606477 hasRelatedWork W2412747875 @default.
- W2017606477 hasRelatedWork W8919293 @default.
- W2017606477 hasVolume "15" @default.
- W2017606477 isParatext "false" @default.
- W2017606477 isRetracted "false" @default.
- W2017606477 magId "2017606477" @default.
- W2017606477 workType "article" @default.